Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab
Real-World-Immune-related Adverse Events bei Patient:innen mit frühem triple-negativem Mammakarzinom unter Pembrolizumab
JCO Oncology Practice · 2025-09 · 21 (9) · 1265-1273
DOI: 10.1200/op.24.00371 ↗Auf einen Blick
In einer realen Kohorte entwickelten 34 % der 233 Patient:innen unter Pembrolizumab irAEs. Am häufigsten waren endokrine und gastrointestinale Ereignisse; 26 waren Grad ≥3 und führten alle zu einer Hospitalisierung.
Fragestellung
Wie häufig und wie schwer waren immunvermittelte Nebenwirkungen bei Patient:innen mit frühem triple-negativem Mammakarzinom unter Pembrolizumab in der Routineversorgung?
Methode
Retrospektive Studie an einem Krebszentrum und einem kommunalen Krankenhaus mit Patient:innen mit TNBC unter Pembrolizumab plus Chemotherapie zwischen 2021 und 2023; Einstufung nach nationalen Leitlinien; logistische Regression.
Ergebnisse
233 Patient:innen; medianes Alter 51 Jahre. 80 (34 %) entwickelten 100 separate irAEs. Häufig: Endokrinopathien 52 % und GI 23 %. 26 Grad-≥3-irAEs, 45 benötigten Steroide, 16 weitere Immunsuppression, 32 setzten Pembrolizumab ab.
Einschränkungen
Retrospektive Studie; nur 2 Zentren; Patient:innen in klinischen Studien ausgeschlossen.
Schlussfolgerung der Autor:innen
In dieser realen, diversen Population waren irAEs ähnlich häufig wie in KEYNOTE-522; endokrine und gastrointestinale irAEs waren am häufigsten und teils schwer. Das ist bei zunehmendem Einsatz von Pembrolizumab relevant.
Kernaussagen
- 34 % entwickelten irAEs unter Pembrolizumab.
- Endokrinopathien waren am häufigsten, GI-irAEs ebenfalls häufig und schwer.
- Kein klinisch-pathologischer Faktor war mit irAEs assoziiert.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-09. Verfasst von Athira Jayan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
PURPOSE The addition of pembrolizumab to chemotherapy in high-risk early triple-negative breast cancer (TNBC) improves cancer outcomes. However, pembrolizumab induces varied immune-related adverse events (irAEs) where some can be severe or lifelong. This retrospective study describes real-world patterns of irAEs in patients with TNBC who received pembrolizumab. METHODS We evaluated irAEs in patients with TNBC from a comprehensive cancer center and a community hospital who received pembrolizumab with chemotherapy between 2021 and 2023, excluding those enrolled in clinical trials. We used national guidelines to grade toxicities. Logistic regression assessed the effect of clinicopathologic variables on irAEs adjusting for covariates. RESULTS We identified 233 patients with a median age of 51 years, 62% had stage II TNBC, 35% had stage III TNBC, 25% were Hispanic, 21% were Black, and 42% were White. Eighty patients (34%) developed 100 separate irAEs. The most common irAEs were endocrinopathies (52%) and GI (23%); there were 26 grade ≥3 irAEs, which all resulted in hospitalization, the most common being GI (13 instances); 45 required systemic steroids, 16 required additional immunosuppressive therapy, and 32 patients discontinued pembrolizumab because of irAEs. Two patients who developed colitis eventually died due to complications. Most (67 instances) irAEs were unresolved at the time of last follow-up, but 55% (37/67) had improved to grade 1. No clinicopathologic factors were associated with the development or severity of irAEs. CONCLUSION In this real-world diverse population, we observed rates of irAEs comparable with KEYNOTE-522, where endocrinopathies were the most prevalent, but GI irAEs were also prevalent and severe. This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX.
- Department of General Internal Medicine, MD Anderson Cancer Center, Houston, TX.
- Department of General Oncology, MD Anderson Cancer Center, Houston, TX.
- Department of Biostatistics, MD Anderson Cancer Center, Houston,TX.
- Department of Health Disparities Research, MD Anderson Cancer Center, Houston, TX.
- Department of Cancer Medicine, MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Athira Jayan, Jasmine S Sukumar, Benjamin Fangman, Tejal Patel, Akshara Singareeka Raghavendra, Ronald Rauch, Karen Basen-Engquist, Debasish Tripathy, Yinghong Wang, Sonya S Khan, Carlos H Barcenas
Förderung
- NCI NIH HHS
Zitieren
APA
Jayan, A., Sukumar, J. S., Fangman, B., Patel, T., Raghavendra, A. S., Liu, D., Pasyar, S., Rauch, R., Basen-Engquist, K., Tripathy, D., Wang, Y., Khan, S. S., & Barcenas, C. H. (2025). Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncology Practice, 21(9), 1265-1273. https://doi.org/10.1200/op.24.00371
Vancouver
Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra AS, Liu D, et al. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncology Practice. 2025;21(9):1265-1273. doi:10.1200/op.24.00371
BibTeX
@article{Jayan2025,
author = {Jayan, Athira and Sukumar, Jasmine S and Fangman, Benjamin and Patel, Tejal and Raghavendra, Akshara Singareeka and Liu, Diane and Pasyar, Sarah and Rauch, Ronald and Basen-Engquist, Karen and Tripathy, Debasish and Wang, Yinghong and Khan, Sonya S and Barcenas, Carlos H},
title = {Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {9},
pages = {1265--1273},
doi = {10.1200/op.24.00371}
}
EUVIMED